Sava Raises $19M Series A to Advance Its Pain-Free Wearable Biosensor for Continuous Health Monitoring
July 30, 2025
Sava Technologies, the London-based biosensing company founded by Imperial College London bioengineers Renato Circi and Rafaël Michali, raised $19 million in a Series A funding round in July 2025, led by Balderton Capital and Pentland Ventures, with participation from Norrsken VC, JamJar Investments, True, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures. The round brings Sava’s total funding to $32 million. The capital will fund team expansion, manufacturing scale-up, and acceleration of the clinical validation programme required to support regulatory approval.
Continuous glucose monitoring has transformed diabetes management for a minority of patients, but its adoption remains constrained by cost, comfort, and the limited accuracy of most current devices. The broader promise of continuous biosensing — real-time, non-invasive monitoring of a wide range of biomarkers that matter to health beyond glucose — has remained largely unfulfilled. Most wearable health devices measure physiological signals (heart rate, skin temperature, movement) rather than molecular-level data. The holy grail of this category is a device that can monitor the actual biochemistry of the body in real time, providing data on metabolites, proteins, and other markers that currently require blood draws or laboratory analysis.
Sava’s core innovation is a proprietary multi-molecule biosensor that can detect biomarkers from just beneath the skin in real time, without requiring a blood sample. The device sits in a wearable form factor and transmits data to a smartphone, providing continuous molecular insights rather than discrete readings. In a clinical trial conducted independently across Oxford and Cambridge sites — enrolling 50 patients with Type 1 and insulin-dependent Type 2 diabetes — early results from the first 25 participants demonstrated accurate, reliable glucose readings for up to 10 days of continuous use, a milestone that significantly outperforms current microsensor platforms, which typically struggle beyond five days. The trial was designed in collaboration with leading diabetes clinicians and regulators to establish the evidence base for subsequent regulatory submissions.
The Series A proceeds will support the growth of Sava’s clinical and engineering teams, scale up automated manufacturing to meet launch volumes, and fund the pivotal clinical study planned for 2026 ahead of regulatory submission. Beyond glucose, Sava’s multi-sensor architecture is designed to expand to additional biomarkers over time, creating the foundation for a continuous molecular health monitoring platform of much broader clinical utility.
Balderton Capital’s lead investment and Pentland Ventures’ participation reflect confidence not just in the near-term CGM opportunity — a market already generating over $11 billion in annual revenue from just 1% of diabetics globally — but in the longer-term biosensing platform potential. Charlie Rubin of Pentland Ventures cited Sava’s world-first technology and breakthrough clinical trial results as the basis for his conviction that the company is “positioned to lead the next wave of innovation in the $100B+ global health wearables market.”
Sources
Thank you to our Patrons & Partners:
